Skip to main content

Table 1 Patient TNFi therapy exposure and bDMARD switching

From: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

 All
(n = 2795)
North America
(n = 530)
LatAm
(n = 137)
EU5
(n = 1478)
APAC
(n = 335)
T&ME
(n = 315)
Number of previous TNFi therapies ever received, n (%)
 0916 (32.8)108 (20.4)15 (10.9)535 (36.2)103 (30.7)155 (49.2)
 11623 (58.1)347 (65.5)113 (82.5)821 (55.5)194 (57.9)148 (47.0)
 2200 (7.2)60 (11.3)9 (6.6)89 (6.0)31 (9.3)11 (3.5)
 3+56 (2.0)15 (2.8)0 (0.0)33 (2.2)7 (2.1)1 (0.3)
Time on 1st bDMARD despite primary lack of efficacy, months(n = 34)(n = 16) (n = 13)(n = 2)(n = 3)
 Mean (SD)11.1 (10.2)12.6 (11.6)10.7 (9.7)1 (0.0)11.3 (5.0)
 Median9.511.09.01.012.0
 Min, Max0.0–36.02.0–36.00.0–36.01.0–1.06.0–16.0
 IQR0.0, 1.00.0, 1.50.0, 0.00.0, 1.00.0, 0.50.0, 0.0
  1. Abbreviations: APAC Asia Pacific region, bDMARD biological disease modifying anti-rheumatic drug; BMI body mass index, EU5 European Union 5, IQR interquartile range, LatAm Latin America, T&ME Turkey and Middle East, SD standard deviation, TNFi tumour necrosis factor inhibitor